Saturday, July 11, 2026

Drug profile · INN

vincristine

vincristine (DBL VINCRISTINE SULFATE) is a tubulin inhibitor. Associated with Pfizer Australia Pty Ltd.

TGA: approved NMPA: clinical trials
Patents linked 2
Pipeline programs 38
News articles 0
Drug details — vincristine

Quick answer

vincristine (DBL VINCRISTINE SULFATE) is a tubulin inhibitor. Associated with Pfizer Australia Pty Ltd.

Key facts

INN vincristine
Brand DBL VINCRISTINE SULFATE
Mechanism Tubulin inhibitor

Mechanism of action

Tubulin inhibitor

Approval history

Authority Status Date
TGA approved
NMPA clinical trials

Pipeline programs

  1. 2019/2894 Phase 3 · George Institute for · Patients with High Risk Neuroblastoma
  2. 20190360 Phase 3 · Amgen · Newly diagnosed Philadelphia-negative B-cell precursor Acute
  3. CA073-1003 Phase 3 · Celgene · Relapsed/Refractory Follicular Lymphoma
  4. CA073-1020 Phase 3 · Celgene · High-risk Large B-cell Lymphoma
  5. D7402C00001 Phase 3 · AstraZeneca · Large B-cell Lymphoma
  6. D8227C00001 Phase 3 · Anaxis Pharma · Diffuse large B-cell lymphoma
  7. DAY101-002 Phase 3 · Anaxis Pharma · Pediatric low-grade glioma harboring an activating RAF alter
  8. FIL_FOLL19 Phase 3 · Telethon Foundation · Follicular Lymphoma
  1. US 9801874

    Method for the preparation of liposome encapsulated vincristine for therapeutic use

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 9636301

    In vitro release assay for liposome encapsulated vincristine

    Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is vincristine?

vincristine (DBL VINCRISTINE SULFATE) is a tubulin inhibitor. Associated with Pfizer Australia Pty Ltd.

What is the brand name for vincristine?

DBL VINCRISTINE SULFATE is a marketed brand name for vincristine. Check FDA Drugs@FDA for the current US label holder and prescribing information.